MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the sale and
maturity of marketable...
$68,300K
Net cash provided by
investing activities
$37,368K
Canceled cashflow
$30,932K
Increase (decrease) in
cash and cash...
$4,101K
Canceled cashflow
$33,267K
Purchases of marketable
securities
$30,932K
Trade receivables,
prepaid expenses and...
-$4,214K
Share-based compensation
$2,308K
Depreciation
$23K
Net cash used in
operating activities
-$33,124K
Net cash used in
financing activities
-$143K
Canceled cashflow
$6,545K
Income (loss) from
discontinued operations, net...
$253K
Net loss
-$26,483K
Trade payables,
accrued expenses,...
-$12,309K
Withholdings from exercise of
options and issuance of...
-$143K
Canceled cashflow
$253K
Amortization of premium or
discount on marketable...
-$778K
Operating lease
liabilities
-$99K
Loss from continuing
operations
-$26,736K
Other income, net
$3,017K
Loss from continuing
operations before income...
-$26,732K
Income tax expense
$4K
Canceled cashflow
$3,017K
Royalty
revenues-Royalty
$570K
Operating loss
-$29,749K
Canceled cashflow
$570K
Total operating
expenses
$30,319K
General and
administrative
$11,082K
Research and
development-Repibresib VYN201
$8,487K
Research and
development-Research And Development...
$7,756K
Other segment items
$2,994K
Back
Back
Cash Flow
source: myfinsight.com
VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. (VYNE)